A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Increasing use of blood tests to detect prostate cancer is leading to overworked doctors. NTNU has now created an AI diagnostic tool that can help lighten the burden. Diagnostic tools based on ...

PSMA PET-CT is a diagnosit tool helping save men's lives with prostate cancer that has spread beyond the prostate gland Dr. David Samadi says that men with aggressive prostate cancer or a very high ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Prostate cancer is the most common form of cancer among men in Western countries. The disease is naturally linked to aging. Professor Tone Frost Bathen at NTNU leads a number of research projects on ...

The campaign for better prostate cancer awareness has provoked important questions about the lack of testing and screening. Why are men dying unnecessarily?

For men at the highest risk of prostate cancer as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been ...